L/T/N型與L型鈣離子通道阻斷劑用於早期及晚期慢性腎臟病之高血壓、蛋白尿及腎功能之影響：系統性回顧、統合分析及臨床試驗計畫書

Abstract

近年來，慢性腎臟病（Chronic Kidney Disease, CKD）的發病率於全球與台灣均呈現持續增長趨勢，其中高血壓不僅為加速腎病變惡化之核心病因，亦為其不可忽視的常見伴隨症狀。於臨床管理上，積極阻斷蛋白尿分泌並落實嚴格的血壓控制，乃是延緩腎功能退化、抑制心血管不良事件發生之關鍵方針。即便現行國際臨床指引高度共識優先處方腎素-血管收縮素-醛固酮系統（RAAS）抑制劑（如ACEI/ARB）作為初始第一線藥物，但此類高危險群常合併顯著的血管僵硬或體液滯留，且隨控壓標準日趨積極嚴苛，單藥治療往往難以令血壓順利達標。基於此，合併處方鈣離子通道阻斷劑（CCBs）遂成為當前實務上最為廣泛採納的聯合降壓手段。 值得注意的是，傳統L型CCB（以Amlodipine為代表）雖具備優異的體循環降壓效能，然其藥理標的偏向局部擴張腎臟的入球小動脈（Afferent arteriole），對出球小動脈（Efferent arteriole）之舒張效果則相對匱乏。這種選擇性的不對稱微血管擴張，反易誘發腎絲球內壓（Intraglomerular pressure）代償性升高，長期以往可能對脆弱的腎實質造成額外水力拉傷與損傷。相形之下，具備L/T/N型多重通道拮抗效應的下一代CCB（如Benidipine等），能藉由阻斷T型與N型鈣離子通道，達成均衡擴張入球及出球小動脈之特殊效益。此一獨特機制在維持優良降壓效果之餘，更可實質調降腎絲球內部的高壓狀態，進而展現削弱白蛋白尿排泄及保障腎臟功能（Renoprotective effect）的臨床優勢。 縱然理論上L/T/N型CCB的局部腎臟減壓機制顯著優於傳統L型，且先前已有統合分析指明其降壓療效相仿、卻額外附帶降蛋白尿好處，但當前醫學界仍存有一核心爭議：面對早中期 CKD（Stage 1-3或一般微量白蛋白尿患者）與腎絲球已大面積硬化、血流動力學代償機制遭破壞的晚期 CKD（Advanced CKD, Stage 4-5）患者時，L/T/N 型 CCB 能否在不同病程中均穩定維持其超越 L型CCB的抗蛋白尿效益與長期腎預後？針對此期別特異性（Stage-specific）的系統性證據，目前仍處於缺乏全面統合的階段。 為釐清上述關鍵臨床爭議，本研究透過系統性文獻回顧與統合分析（Systematic Review and Meta-analysis）架構，嚴謹比對並評估L/T/N型與傳統L型CCB於晚期（eGFR < 60 mL/min/1.73 m²）與早期（eGFR ≥ 60 mL/min/1.73 m²）慢性腎臟病患者中，其在體循環血壓控制及尿蛋白改善幅度上的本質差異。尤為關鍵的是，本研究依據統合分析所揭示的臨床實證缺口，進一步擬定並設計了一份前瞻性臨床試驗計畫書草案（Clinical Trial Protocol）。此試驗架構旨在為未來開發兼具優異器官保護力之新型固定劑量複方藥物（Fixed-Dose Combination, FDC，如融合特定CCB與 ARB）提供符合發照法規規格的Phase 3臨床試驗指引，期能為慢性腎臟病伴隨高血壓之高風險病患，提供更為優化且精準的醫療防禦處方。

Title: Hypertension, Proteinuria and Renal Function Outcomes with L/T/N-type versus L-type Calcium Channel Blockers in Early and Advanced Chronic Kidney Disease: A Systematic Review/ Meta-analysis and a Clinical Trial Protocol Background The prevalence of chronic kidney disease (CKD) is continuously rising both globally and in Taiwan. Hypertension serves as a core pathological driver accelerating renal deterioration, while remaining a ubiquitous comorbidity. In clinical management, suppressing proteinuria and achieving strict blood pressure (BP) control are paramount to delaying renal function decline and reducing adverse cardiovascular events. Although international clinical guidelines establish renin-angiotensin-aldosterone system inhibitors (RAASi) as the first-line therapy, monotherapy is frequently insufficient due to profound arterial stiffness or fluid overload in this high-risk population, necessitating combination therapy. Calcium channel blockers (CCBs) are the most widely adopted add-on agents. However, traditional L-type CCBs (e.g., amlodipine) preferentially dilate renal afferent arterioles without a corresponding effect on efferent arterioles, potentially elevating intraglomerular pressure and causing hydrostatic injury over time. Conversely, next-generation L/T/N-type CCBs (e.g., benidipine) induce balanced vasodilation of both afferent and efferent arterioles by blocking T- and N-type channels, thereby reducing intraglomerular hypertension and offering superior renoprotective benefits. Whether this antiproteinuric advantage is maintained across different stages of CKD remains a critical, unresolved clinical question due to a lack of comprehensive, stage-specific evidence. Methods A systematic literature search was executed across PubMed, EMBASE, and the Cochrane Library up to January 2026 to identify randomized controlled trials (RCTs) evaluating L/T/N-type versus L-type CCBs in adult hypertensive CKD patients optimized on background RAASi. Pooled effect sizes for changes in proteinuria excretion as standardized mean differences (SMDs), systolic blood pressure (SBP), and diastolic blood pressure (DBP) were calculated as a mean difference (MDs) using a random-effects model with Knapp-Hartung (HK) adjustments. Pre-specified subgroup analyses were stratified by baseline renal function: early-stage CKD (mean baseline eGFR ≥ 60 mL/min/1.73 m²) versus advanced-stage CKD (mean baseline eGFR < 60 mL/min/1.73 m²). Addressing the clinical evidence gap identified by the meta-analysis, a prospective, regulatory-compliant Phase III clinical trial protocol was developed. Results Ten RCTs involving a total of 952 patients (477 in the L/T/N-type CCB group and 475 in the L-type CCB group) met the eligibility criteria. The overall pooled analysis demonstrated that L/T/N-type CCBs achieved a statistically significant reduction in urinary protein excretion compared to traditional L-type CCBs (SMD = -0.98; 95% CI: -1.67 to -0.28, p = 0.0113), accompanied by substantial statistical heterogeneity (I2 = 93.8%). Crucially, the pre-specified subgroup analysis revealed a highly significant interaction effect (p = 0.0003), demonstrating that baseline eGFR strongly modifies antiproteinuric efficacy. In the advanced CKD subgroup (6 trials, n = 402), L/T/N-type CCBs exhibited a highly pronounced and superior reduction in proteinuria (SMD = -1.52; 95% CI: -2.39 to -0.66). Conversely, no significant difference in proteinuria reduction was detected in the early CKD subgroup (4 trials, n = 550; SMD = -0.10; 95% CI: -0.74 to 0.54). Regarding systemic hemodynamics, SBP and DBP reductions were equivalent and virtually identical between both treatment classes across all stages (p > 0.05), indicating that the superior renoprotective advantage of L/T/N-type CCBs in advanced CKD is independent of systemic blood pressure reduction and driven by direct intrarenal mechanisms. Conclusions The superior renoprotective efficacy of L/T/N-type CCBs over traditional L-type CCBs is stage-specific and predominantly driven by patients with moderately to severely impaired renal function (eGFR < 60) via blood pressure-independent intrarenal pathways. To translate these empirical findings into optimized clinical care, the designed Phase III clinical study protocol establishes a comprehensive, regulatory-compliant framework to evaluate a novel fixed-dose combination (FDC) strategy. This dual-mechanism intervention aims to maximize microvascular protection, simplify complex therapeutic regimens, and significantly enhance long-term treatment adherence in this highly vulnerable cardiorenal metabolic population.